EHA 2023

EHA 2023
June 08-11, 2023
Frankfurt, Germany

European Hematology Association.

Explore more information for Gilead Oncology therapies
Results (1)

Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients With Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)